European Commission Orders HIPRA’s COVID-19 Vaccine

The European Commission has inked a procurement deal with Spain-based biotech company HIPRA for up to 250 million doses of its COVID-19 vaccine of behalf of EU members states.

The recombinant protein vaccine, which does not use messenger RNA technology, is still investigational, but it has gone through several clinical trials including a late-stage study launched earlier this year.

The European Commission said that 14 EU Member States and countries are participating in the procurement deal. The purchase price was not disclosed.

The commission is expected to grant the vaccine a conditional authorization sometime this year.